Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antibody production.

John R Birch1, Andrew J Racher

  • 1Lonza Biologics plc, 228 Bath Road, Slough, Berkshire, SL1 4DX, UK. john.birch@lonza.com

Advanced Drug Delivery Reviews
|July 11, 2006
PubMed
Summary
This summary is machine-generated.

Monoclonal antibody production in mammalian cell culture has seen a 100-fold productivity increase due to improved expression and fed-batch processes. Future trends focus on faster cell line development for quicker clinical material production.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Directed evolution of biomass intensive CHO cells by adaptation to sub-physiological temperature.

Metabolic engineering·2023
Same author

A proline metabolism selection system and its application to the engineering of lipid biosynthesis in Chinese hamster ovary cells.

Metabolic engineering communications·2021
Same author

Data for engineering lipid metabolism of Chinese hamster ovary (CHO) cells for enhanced recombinant protein production.

Data in brief·2020
Same author

Engineering of Chinese hamster ovary cell lipid metabolism results in an expanded ER and enhanced recombinant biotherapeutic protein production.

Metabolic engineering·2019
Same author

Intact-Cell MALDI-ToF Mass Spectrometry for the Authentication of Drug-Adapted Cancer Cell Lines.

Cells·2019
Same author

Improving the accuracy of flux balance analysis through the implementation of carbon availability constraints for intracellular reactions.

Biotechnology and bioengineering·2019
Same journal

Silicone oil in protein drug products and its implications for formulation stability.

Advanced drug delivery reviews·2026
Same journal

Targeted delivery of proteolysis-targeting chimeras (PROTAC) and molecular glue degraders (MGD).

Advanced drug delivery reviews·2026
Same journal

Lysosome-targeting degrader delivery system: from formulation design to biomedical applications.

Advanced drug delivery reviews·2026
Same journal

Anti-PEG antibodies in nanomedicine: Mechanisms, risks, and opportunities.

Advanced drug delivery reviews·2026
Same journal

Optimizing macrophage-targeted intracellular delivery systems for safe and effective immunotherapies.

Advanced drug delivery reviews·2026
Same journal

Light-controlled CRISPR-dCas9 epigenome editing: advanced drug-delivery strategies and oncology applications.

Advanced drug delivery reviews·2026
See all related articles

Area of Science:

  • Biotechnology
  • Biopharmaceutical Manufacturing
  • Cell Culture Technology

Background:

  • The widespread clinical and commercial success of monoclonal antibodies necessitates large-scale production.
  • This has driven significant global expansion in manufacturing capacity, including larger bioreactors (up to 20,000 L).
  • There is a continuous effort to enhance process efficiency and reduce manufacturing costs.

Purpose of the Study:

  • To review current technologies for monoclonal antibody production, focusing on mammalian cell culture.
  • To discuss advancements in upstream processing, including expression technology and fed-batch cultures.
  • To explore future trends in monoclonal antibody manufacturing, particularly in accelerating process development and cell line creation.

Main Methods:

Related Experiment Videos

  • Review of existing literature and industry practices in mammalian cell culture for monoclonal antibody production.
  • Analysis of improvements in expression technology and process optimization strategies.
  • Discussion of cell line development timelines and potential future innovations.

    • Main Results:

    • Upstream processing productivity has improved 100-fold over the last 15 years.
    • Improvements stem from enhanced expression systems and optimized fed-batch culture techniques.
    • Cell line creation remains a critical bottleneck in reducing overall process development time.

    Conclusions:

    • Mammalian cell culture is a cornerstone of modern monoclonal antibody manufacturing.
    • Significant progress has been made in upstream productivity, but cell line development requires further acceleration.
    • Future efforts will likely focus on streamlining early-stage development to expedite the availability of therapeutic materials.